t
AOTI, INC. announced on 23 April 2025 that its Chief Executive Officer and President, Dr. Mike Griffiths, and Chief Financial Officer, Jayesh Pankhania, will provide a live presentation. This presentation, relating to the Company's Preliminary Results, is scheduled for 28 April 2025 at 11:30 BST via Investor Meet Company, with pre-event questions accepted until 27 April 2025 at 09:00 BST.
| Date | 23 Apr 2025 |
| Time | 07:00:09 |
| Category | Miscellaneous |
| ID | 7526F |
23 April 2025
AOTI, INC. (the "Company" or "Group" or "AOTI")
Investor Presentation via Investor Meet Company
AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable healing of wounds and the prevention of amputations, is pleased to announce that Dr. Mike Griffiths, Chief Executive Officer and President, and Jayesh Pankhania, Chief Financial Officer, will provide a live presentation relating to the Company's Preliminary Results via Investor Meet Company on 28 April 2025 at 11:30 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 27 April 2025, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet AOTI, INC. via:
https://www.investormeetcompany.com/aoti-inc/register-investor
Investors who already follow AOTI, INC. on the Investor Meet Company platform will automatically be invited.
ENDS
|
AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
|
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins, Alex Davis |
+44 (0)20 3727 1000 |
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net